FDA Clears IND Application for GALGT2 Gene Therapy for Duchenne Muscular Dystrophy – Muscular Dystrophy News
Muscular Dystrophy News |
FDA Clears IND Application for GALGT2 Gene Therapy for Duchenne Muscular Dystrophy
Muscular Dystrophy News The U.S. Food and Drug Administration (FDA) recently cleared an investigational new drug (IND) application for the GALGT2 gene therapy program for Duchenne muscular dystrophy (DMD) filed by Sarepta Therapeutics and Nationwide Children's Hospital. Sarepta Therapeutics (SRPT): FDA Clears GALGT2 Gene Therapy Program – William Blair Sarepta Therapeutics and Nationwide Children's Hospital Announce FDA Clearance of IND for Micro-Dystrophin Gene … Sarepta Therapeutics And Nationwide Children's Hospital Announce US Food And Drug Administration (FDA … |
